Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Jaran Eriksen, Christina Carlander, Jan Albert, Leo Flamholc, Magnus Gisslén, Lars Navér, Veronica Svedhem, Aylin Yilmaz & Anders Sönnerborg. (2020) Antiretroviral treatment for HIV infection: Swedish recommendations 2019. Infectious Diseases 52:5, pages 295-329.
Read now
Read now
Paula Prieto & Daniel Podzamczer. (2019) Switching strategies in the recent era of antiretroviral therapy. Expert Review of Clinical Pharmacology 12:3, pages 235-247.
Read now
Read now
Jaran Eriksen, Jan Albert, Anders Blaxhult, Christina Carlander, Leo Flamholc, Magnus Gisslén, Filip Josephson, Olof Karlström, Lars Navér, Veronica Svedhem, Aylin Yilmaz & Anders Sönnerborg. (2017) Antiretroviral treatment for HIV infection: Swedish recommendations 2016. Infectious Diseases 49:1, pages 1-34.
Read now
Read now
Camille Bernaud, Lydie Khatchatourian, Audrey Rodallec, Nolwenn Hall, Philippe Perre, Marine Morrier, Solène Pineau, Thomas Jovelin, Elisabeth André-Garnier, François Raffi & Clotilde Allavena. (2016) Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection*. Infectious Diseases 48:10, pages 754-759.
Read now
Read now
Laia Utrillo, Francesc Vidal, Teresa Puig & Pere Domingo. (2016) Switching antiretroviral regimes for the treatment of HIV: safety implications. Expert Opinion on Drug Safety 15:10, pages 1349-1360.
Read now
Read now
Pornpimol Thamrongwonglert, Ploenchan Chetchotisakd, Siriluck Anunnatsiri & Piroon Mootsikapun. (2016) Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia. HIV Clinical Trials 17:1, pages 12-16.
Read now
Read now
Danielle P. Porter, Rima Kulkarni, Todd Fralich, Michael D. Miller & Kirsten L. White. (2015) 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects. HIV Clinical Trials 16:1, pages 30-38.
Read now
Read now
Diego Ripamonti, Enrico Bombana & Marco Rizzi. (2014) Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor. Expert Review of Anti-infective Therapy 12:1, pages 13-29.
Read now
Read now
Articles from other publishers (50)
Alessandro Cozzi-Lepri, Lars Peters, Annegret Pelchen-Matthews, Bastian Neesgaard, Stephane De Wit, Isik Somuncu Johansen, Simon Edwards, Christoph Stephan, Georgios Adamis, Therese Staub, Alexandra Zagalo, Pere Domingo, Daniel Elbirt, Katharina Kusejko, Johanna Brännström, Dzmitry Paduta, Tatyana Trofimova, Janos Szlavik, Kai Zilmer, Marcello Losso, Veerle Van Eygen, Helen Pai, Jens Lundgren, Amanda Mocroft, A. Harxhi, M. Losso, M. Kundro, B. Schmied, I. Karpov, A. Vassilenko, D. Paduto, V. M. Mitsura, N. Clumeck, S. De Wit, M. Delforge, V. Hadziosmanovic, J. Begovac, L. Machala, D. Jilich, J. Gerstoft, C. Pedersen, D. Sedlacek, G. Kronborg, T. Benfield, I. S. Johansen, L. Ostergaard, L. Wiese, N. F. Moller, L. N. Nielsen, K. Zilmer, Jelena Smidt, I. Aho, J. P. Viard, P. M. Girard, C. Pradier, E. Fontas, C. Duvivier, J. Rockstroh, O. Degen, C. Hoffmann, H. J. Stellbrink, C. Stefan, J. Bogner, G. Fätkenheuer, N. Chkhartishvili, H. Sambatakou, G. Adamis, N. Paissios, V. Uzdaviniene, T. Staub, S. Dragas, P. Reiss, J. Trajanovska, D. H. Reikvam, A. Maeland, J. Bruun, B. Knysz, B. Szetela, M. Inglot, E. Bakowska, R. Flisiak, A. Grzeszczuk, M. Parczewski, K. Maciejewska, B. Aksak-Was, M. Beniowski, E. Mularska, E. Jablonowska, J. Kamerys, K. Wojcik, I. Mozer-Lisewska, B. Rozplochowski, A. Zagalo, R. Radoi, C. Oprea, A. Yakovlev, T. Trofimora, I. Khromova, E. Kuzovatova, E. Borodulina, E. Vdoushkina, J. Ranin, J. Tomazic, J. M. Miro, M. Laguno, E. Martinez, F. Garcia, J. L. Blanco, M. Martinez-Rebollar, J. Mallolas, P. Callau, J. Rojas, S. Moreno, S. del Campo, A. Jou, R. Paredes, J. Puig, J. M. Llibre, J. R. Santos, P. Domingo, M. Gutierrez, G. M. Mateo, A. Sambeat, J. M. Laporte, V. Svedhem, A. Thalme, A. Sonnerborg, L. Flamholc, K. Kusejko, R. Weber, A. Calmy, H. Furrer, M. Battegay, P. Schmid, A. Kuznetsova, J. Mikhalik, M. Sluzhynska, A. Milinkovic, A. M. Johnson, E. Simons, S. Edwards, A. M. Phillips, A. Johnson, A. Mocroft, C. Orkin, A. Winston, A. Clarke & C. Leen. (2022) Observational cohort study of rilpivirine (RPV) utilization in Europe. AIDS Research and Therapy 19:1.
Crossref
Crossref
Madhu C Choudhary & John W Mellors. (2022) The transformation of HIV therapy: One pill once a day. Antiviral Therapy 27:2, pages 135965352110623.
Crossref
Crossref
Filippo Lagi, Annarita Botta, Seble Tekle Kiros, Massimo Meli, Beatrice Borchi, Annalisa Cavallo, Marco Pozzi, Alessandro Bartoloni & Gaetana Sterrantino. (2022) Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis. International Journal of Antimicrobial Agents 59:1, pages 106465.
Crossref
Crossref
Wanatpreeya Phongsamart, Watsamon Jantarabenjakul, Sasitorn Chantaratin, Suvaporn Anugulruengkitt, Piyarat Suntarattiwong, Pakpen Sirikutt, Pope Kosalaraksa, Alan Maleesatharn & Kulkanya Chokephaibulkit. (2022) Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi‐centre 48‐week efficacy and safety study in Thailand. Journal of the International AIDS Society 25:1.
Crossref
Crossref
Nadège Néant, Minh Patrick Lê, Naïm Bouazza, Florence Gattacceca, Yazdan Yazdanpanah, Catherine Dhiver, Sylvie Bregigeon, Saadia Mokhtari, Gilles Peytavin, Catherine Tamalet, Diane Descamps, Bruno Lacarelle & Caroline Solas. (2020) Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV‐infected patients. British Journal of Clinical Pharmacology 86:12, pages 2404-2413.
Crossref
Crossref
Aaron Richterman & Paul E. Sax. (2020) Antiretroviral therapy in older people with HIV. Current Opinion in HIV and AIDS 15:2, pages 118-125.
Crossref
Crossref
Sung-Hsi Huang, Shu-Wen Lin, Sui-Yuan Chang, Ya-Ting Lin, Hsin-Yun Sun, Wen-Chun Liu, Yi-Ching Su, Chien-Ching Hung & Shan-Chwen Chang. (2020) Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study. Journal of Microbiology, Immunology and Infection 53:1, pages 60-68.
Crossref
Crossref
Carey Hwang, Ming-Tain Lai & Daria Hazuda. (2019) Rational Design of Doravirine: From Bench to Patients. ACS Infectious Diseases 6:1, pages 64-73.
Crossref
Crossref
James Cutrell, Tomasz Jodlowski & Roger Bedimo. (2020) The management of treatment-experienced HIV patients (including virologic failure and switches). Therapeutic Advances in Infectious Disease 7, pages 204993612090139.
Crossref
Crossref
Sivaporn Gatechompol, Anchalee Avihingsanon, Tanakorn Apornpong, Win Min Han, Stephen J. Kerr & Kiat Ruxrungtham. (2019) Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice. AIDS Research and Therapy 16:1.
Crossref
Crossref
Vera, Bracchi, Alagaratnam, Lwanga, Fox, Winston, Boffito & Nelson. (2019) Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART. Brain Sciences 9:8, pages 195.
Crossref
Crossref
Porkaew Petchkum, Somnuek Sungkanuparph, Sasisopin Kiertiburanakul & Angsana Phuphuakrat. (2019) Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial. Open Forum Infectious Diseases 6:4.
Crossref
Crossref
Daniel Chastain, Melissa Badowski, Emily Huesgen, Neha Sheth Pandit, Andrea Pallotta & Sarah Michienzi. (2019) Optimizing Antiretroviral Therapy in Treatment-Experienced Patients Living with HIV: A Critical Review of Switch and Simplification Strategies. An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy. Journal of the International Association of Providers of AIDS Care (JIAPAC) 18, pages 232595821986732.
Crossref
Crossref
Rebecca Reece, Allison Delong, D’Antuono Matthew, Karen Tashima & Rami Kantor. (2018) Accumulated pre-switch resistance to more recently introduced one-pill-once-a-day antiretroviral regimens impacts HIV-1 virologic outcome. Journal of Clinical Virology 105, pages 11-17.
Crossref
Crossref
Prema MenezesKatie MollanErin HoffmanZimeng XieJennifer WillsCheryl MarcusJohn RubleinMichael HudgensJoseph J. EronJr.Jr.. (2018) Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate. AIDS Research and Human Retroviruses 34:6, pages 481-485.
Crossref
Crossref
Watsamon Jantarabenjakul, Suvaporn Anugulruengkitt, Naruporn Kasipong, Narukjaporn Thammajaruk, Jiratchaya Sophonphan, Torsak Bunupuradah, Tim R Cressey, Angela Colbers, David M Burger, Wanatpreeya Phongsamart, Thanyawee Puthanakit & Chitsanu Pancharoen. (2017) Pharmacokinetics of Rilpivirine and 24-Week Outcomes after Switching from Efavirenz in Virologically Suppressed HIV-1-Infected Adolescents. Antiviral Therapy 23:3, pages 259-265.
Crossref
Crossref
Delphine Sculier, Angèle Gayet-Ageron, Manuel Battegay, Matthias Cavassini, Jan Fehr, Cedric Hirzel, Patrick Schmid, Enos Bernasconi & Alexandra Calmy. (2017) Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. BMC Infectious Diseases 17:1.
Crossref
Crossref
Minh P Lê, Linda Belarbi, Marie-Laure Chaix, Emmanuel Dulioust, Nadia Mahjoub, Dominique Salmon, Jean-Paul Viard, Claudine Duvivier, Gilles Peytavin, Odile Launay & Jade Ghosn. (2017) Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals. Journal of Antimicrobial Chemotherapy 72:11, pages 3167-3171.
Crossref
Crossref
Janessa M. Smith & Charles Flexner. (2017) The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. AIDS 31:Supplement 2, pages S173-S184.
Crossref
Crossref
Jamielynn C. Sebaaly & Denise Kelley. (2016) Single-Tablet Regimens for the Treatment of HIV-1 Infection. Annals of Pharmacotherapy 51:4, pages 332-344.
Crossref
Crossref
Jesús Troya, Pablo Ryan, Esteban Ribera, Daniel Podzamczer, Victor Hontañón, Jose Alberto Terrón, Vicente Boix, Santiago Moreno, Pilar Barrufet, Manuel Castaño, Ana Carrero, María José Galindo, Ignacio Suárez-Lozano, Hernando Knobel, Miguel Raffo, Javier Solís, María Yllescas, Herminia Esteban, Juan González-García, Juan Berenguer & Arkaitz Imaz. (2016) Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLOS ONE 11:10, pages e0164455.
Crossref
Crossref
Duncan Churchill, Laura Waters, Nadia Ahmed, Brian Angus, Marta Boffito, Mark Bower, David Dunn, Simon Edwards, Carol Emerson, Sarah Fidler, Martin Fisher, Rob Horne, Saye Khoo, Clifford Leen, Nicola Mackie, Neal Marshall, Fernando Monteiro, Mark Nelson, Chloe Orkin, Adrian Palfreeman, Sarah Pett, Andrew Phillips, Frank Post, Anton Pozniak, Iain Reeves, Caroline Sabin, Roy Trevelion, John Walsh, Ed Wilkins, Ian Williams & Alan Winston. (2016) British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Medicine 17, pages s2-s104.
Crossref
Crossref
S. Lambert-Niclot, C. Allavena, M. Grude, P. Flandre, S. Sayon, E. Andre, M. Wirden, A. Rodallec, T. Jovelin, C. Katlama, V. Calvez, F. Raffi & A.-G. Marcelin. (2016) Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination. Journal of Antimicrobial Chemotherapy 71:8, pages 2248-2251.
Crossref
Crossref
Srini Ramanathan, Joseph M. Custodio, Xuelian Wei, Hui Wang, Marshall Fordyce, Ami Dave, Kah Hiing J. Ling, Javier Szwarcberg & Brian P. Kearney. (2016) Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes 72:3, pages 281-288.
Crossref
Crossref
Leonardo Calza, Vincenzo Colangeli, Roberto Manfredi, Isabella Bon, Maria Carla Re & Pierluigi Viale. (2016) Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. Journal of Antimicrobial Chemotherapy 71:6, pages 1451-1465.
Crossref
Crossref
Sandrine Gazaignes, Matthieu Resche-Rigon, Caroline Gatey, Chloe Yang, Blandine Denis, Julien Fonsart, Kristell Desseaux, Michel Guionie, Willy Rozenbaum, Constance Delaugerre & Jean-Michel Molina. (2015) Efficacy and Safety of a Switch to Rilpivirine-Based Regimens in Treatment-Experienced HIV-1-Infected Patients: A Cohort Study. Antiviral Therapy 21:4, pages 329-336.
Crossref
Crossref
Rosario Palacios, Marisa Mayorga, Isabel A. Pérez-Hernández, Antonio Rivero, Alfonso del Arco, Fernando Lozano & Jesús Santos. (2016) Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet. Journal of the International Association of Providers of AIDS Care (JIAPAC) 15:3, pages 189-193.
Crossref
Crossref
Sean E. Collins, Philip M. Grant, Francois Uwinkindi, Annie Talbot, Eric Seruyange, Deborah Slamowitz, Adeline Mugeni, Eric Remera, Simon Pierre Niyonsenga, Josbert Nyirimigabo, Jean Paul Uwizihiwe, Pierre Dongier, Ribakare Muhayimpundu, Jean-Baptiste Mazarati, Andrew Zolopa & Sabin Nsanzimana. (2016) A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans. Open Forum Infectious Diseases 3:3.
Crossref
Crossref
R. Palacios, I. A. Pérez-Hernández, M. A. Martínez, M. L. Mayorga, C. M. González-Domenech, M. Omar, J. Olalla, A. Romero, J. M. Romero, I. Pérez-Camacho, J. Hernández-Quero & J. Santos. (2016) Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART. European Journal of Clinical Microbiology & Infectious Diseases 35:5, pages 815-819.
Crossref
Crossref
Meizhen Feng, Nancy A. Sachs, Min Xu, Jay Grobler, Wade Blair, Daria J. Hazuda, Michael D. Miller & Ming-Tain Lai. (2016) Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations. Antimicrobial Agents and Chemotherapy 60:4, pages 2241-2247.
Crossref
Crossref
Antonio Di Biagio, Alessandro Cozzi-Lepri, Roberta Prinapori, Gioacchino Angarano, Andrea Gori, Tiziana Quirino, Andrea De Luca, Andrea Costantini, Cristina Mussini, Giuliano Rizzardini, Antonella Castagna, Andrea Antinori & Antonella d'Arminio Monforte. (2016) Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. JAIDS Journal of Acquired Immune Deficiency Syndromes 71:3, pages 263-271.
Crossref
Crossref
Sean E. Collins, Philip M. Grant & Robert W. Shafer. (2015) Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. Drugs 76:1, pages 75-98.
Crossref
Crossref
Carmela Pinnetti, Simona Di Giambenedetto, Franco Maggiolo, Massimiliano Fabbiani, Gaetana Sterrantino, Alessandra Latini, Patrizia Lorenzini, Adriana Ammassari, Laura Loiacono, Rita Bellagamba, Evangelo Boumis, Roberto Cauda, Andrea Antinori & Mauro Zaccarelli. (2015) Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 70:4, pages e147-e150.
Crossref
Crossref
Nadezda Apostolova, Haryes A. Funes, Ana Blas-Garcia, Maria J. Galindo, Angeles Alvarez & Juan V. Esplugues. (2015) Efavirenz and the CNS: what we already know and questions that need to be answered. Journal of Antimicrobial Chemotherapy 70:10, pages 2693-2708.
Crossref
Crossref
Emma D. Deeks. (2015) Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen in HIV-1 infection: a guide to its use in the EU. Drugs & Therapy Perspectives 31:8, pages 251-258.
Crossref
Crossref
Charlotte Charpentier, Minh Patrick Lê, Véronique Joly, Benoit Visseaux, Sylvie Lariven, Bao Phung, Patrick Yéni, Yazdan Yazdanpanah, Diane Descamps, Gilles Peytavin & Roland Landman. (2015) Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up. PLOS ONE 10:7, pages e0134430.
Crossref
Crossref
Mohammed Lamorde, Stephen Walimbwa, Pauline Byakika-Kibwika, Michael Katwere, Lillian Mukisa, Joseph B. Sempa, Laura Else, David J. Back, Saye H. Khoo & Concepta Merry. (2015) Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. Journal of Antimicrobial Chemotherapy 70:5, pages 1482-1486.
Crossref
Crossref
P Gantner, S Reinhart, M Partisani, M Baldeyrou, M-L Batard, C Bernard-Henry, C Cheneau, E de Mautort, M Priester, S Fafi-Kremer, P Muret & D Rey. (2015) Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study. HIV Medicine 16:2, pages 132-136.
Crossref
Crossref
Nicola Gianotti, Andrea Poli, Silvia Nozza, Vincenzo Spagnuolo, Giuseppe Tambussi, Simona Bossolasco, Paola Cinque, Myriam Maillard, Massimo Cernuschi, Laura Galli, Adriano Lazzarin & Antonella Castagna. (2015) Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. Journal of the International AIDS Society 18:1, pages 20037.
Crossref
Crossref
Laure Surgers, Nadia Valin, Céline Viala, Anders Boyd, Laurent Fonquernie, Pierre-Marie Girard, Laurence Morand-Joubert & Jean-Luc Meynard. (2015) Evaluation of the Efficacy and Safety of Switching to Tenofovir, Emtricitabine, and Rilpivirine in Treatment-Experienced Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 68:1, pages e10-e12.
Crossref
Crossref
Casper Rokx, Maren Blonk, Annelies Verbon, David Burger & Bart J. A. Rijnders. (2015) The Efficacy, Pharmacokinetics, and Safety of a Nevirapine to Rilpivirine Switch in Virologically Suppressed HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 68:1, pages 36-39.
Crossref
Crossref
Charles Cazanave, Sandrine Reigadas, Cyril Mazubert, Pantxika Bellecave, Mojgan Hessamfar, Fabien Le Marec, Estibaliz Lazaro, Gilles Peytavin, Mathias Bruyand, Hervé Fleury, François Dabis & Didier Neau. (2015) Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014. Open Forum Infectious Diseases 2:1.
Crossref
Crossref
C. Amiel, V. Schneider, S. Guessant, M. Hamidi, K. Kherallah, M.-G. Lebrette, J. Chas, C. Lependeven & G. Pialoux. (2014) Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'. Journal of Antimicrobial Chemotherapy 69:12, pages 3335-3339.
Crossref
Crossref
H. Jeulin, M. Foissac, L. Boyer, N. Agrinier, P. Perrier, A. Kennel, A. Velay, F. Goehringer, S. Henard, C. Rabaud, T. May & E. Schvoerer. (2014) Real-life rilpivirine resistance and potential emergence of an E138A-positive HIV strain in north-eastern France. Journal of Antimicrobial Chemotherapy 69:11, pages 3095-3102.
Crossref
Crossref
Emma D. Deeks. (2014) Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Review of Its Use in HIV Infection. Drugs 74:17, pages 2079-2095.
Crossref
Crossref
C. Allavena, E. Dailly, V. Reliquet, B. Bonnet, S. Pineau, E. Andre-Garnier, D. Boutoille, R. Bouquie, A. Raveleau, S. Bouchez, E. Billaud & F. Raffi. (2014) Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. Journal of Antimicrobial Chemotherapy 69:10, pages 2804-2808.
Crossref
Crossref
Katya R. Calvo & Eric S. Daar. (2014) Antiretroviral Therapy. Infectious Disease Clinics of North America 28:3, pages 439-456.
Crossref
Crossref
Rik Schrijvers & Zeger Debyser. (2014) Switching STRATEGIES in HIV treatment. The Lancet Infectious Diseases 14:7, pages 537-540.
Crossref
Crossref
Noemi Astuti & Franco Maggiolo. (2014) Single-Tablet Regimens in HIV Therapy. Infectious Diseases and Therapy 3:1, pages 1-17.
Crossref
Crossref
Kamila Wójcik. (2014) Eviplera® as a switch option for HIV infected patients—Review of GS-US-264-106 (SPIRIT) and GS-US-264-0111 studies. HIV & AIDS Review 13:4, pages 106-108.
Crossref
Crossref